VANCOUVER, British Columbia and LAS VEGAS, April 15, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight”or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a fast-growing mobile clinical network and medical platform which enables flexible at-home medical services across 50 states in the United States, is pleased to announce the expansion of its VSDHOne platform with the launch of Liraglutide. This addition marks a strategic expansion of Hydreight’s growing GLP-1 weight management and wellness offerings, strengthening its commitment to accessible and innovative solutions through its national telehealth network.
Hydreight’s current GLP-1 offerings now include:
- Semaglutide (weekly injectable)
- Tirzepatide (dual-action, weekly injectable)
- Liraglutide (newly launched, daily injectable)
- Sublingual & Buccal GLP-1s (needle-free administration)
These offerings include a range of delivery methods to meet the diverse needs of patients and providers—from weekly or daily injectables to sublingual and buccal formats. Sublingual doses are dissolved under the tongue, and buccal is absorbed through the cheek, offering flexibility for those who prefer not to use needles while maintaining consistent dosage options. This variety ensures tailored, scalable solutions for weight management and metabolic care.
A Strategic Addition for Stability & Choice
As demand for GLP-1 medications surges, Hydreight’s inclusion of Liraglutide introduces a stable, patent-free, and clinically proven option—ideal for patients and providers seeking consistent long-term therapies amid evolving supply and regulatory landscapes. Unlike newer GLP-1 entrants, Liraglutide’s established track record and daily dosing format offer flexibility without compromising efficacy.
“The launch of Liraglutide further deepens our commitment to expanding access to proven GLP-1 therapies,” said Shane Madden, CEO of Hydreight. “It doesn’t replace anything—it expands our offering. No matter how the landscape shifts, Hydreight users can count on a complete and reliable GLP-1 portfolio.”
Why Liraglutide?
Liraglutide is a GLP-1 receptor agonist used in the management of obesity and type 2 diabetes. Delivered via once-daily injection, it offers consistent and clinically proven efficacy. Compared to sublingual GLP-1s, which have lower bioavailability and shorter duration of action, Liraglutide’s injectable form ensures direct systemic absorption and predictable, long-lasting effects.
Comprehensive & Customizable Delivery Options Hydreight’s GLP-1 portfolio now supports multiple delivery methods:
- Injectables: Weekly, biweekly, or daily based on patient needs
- Sublingual: Dissolved under the tongue
- Buccal: Absorbed through the inner cheek
This mix of injectable, sublingual, and buccal options positions Hydreight as a category leader in GLP-1 administration versatility. It allows medical professionals to provide customized, scalable care while ensuring patient adherence and comfort.
Unlocking Access via VSDHOne
The VSDHOne platform enables a seamless patient journey—from telehealth consultation to prescription and nationwide delivery. It supports medical professionals with flexible tools while ensuring regulatory compliance across all services.
“Hydreight isn’t just a tech stack—we’re a full-service medical infrastructure,” added Madden. “With over 400 licenses sold across the U.S., we’re creating a scalable, future-ready solution for wellness, weight loss, and personalized healthcare.”
The addition of Liraglutide and sublingual/buccal routes of administration for the GLP1s reflects Hydreight’s mission to expand access to premium wellness and weight management therapies through a convenient, compliant, and nationwide telehealth network. The VSDHOne platform simplifies the entire patient journey from telehealth consult to prescription and delivery, while offering medical professionals the flexibility to provide treatments at scale.
Liraglutide will be available to all eligible VSDHOne customers, ensuring widespread access to these innovative wellness treatments.
On behalf of the Board of Directors
Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.
Hydreight Technologies Inc Ranked Number 56 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Hydreight Technologies Recognized as a Top 50 TSX Venture Exchange Company
Hydreight Technologies Recognized by the Financial Times Ranking 13th as One of the Americas’ Fastest Growing Companies in 2025
Contact
Email: ir@hydreight.com; Telephone: 1 (702) 970-8112
About Hydreight Technologies Inc.
Hydreight Technologies Inc is building one of the largest mobile clinic network in the United States. Its proprietary, fully integrated platform hosts a network of over 2500 nurses, over 100 doctors and a pharmacy network across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.
This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.
About VSDHOne - Direct to Consumer Platform
Developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight Technologies launched the VSDHOne (Read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s (semaglutide, tirzepatide, liraglutide), peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy (“TRT”), hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.
Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.
Cautionary Note Regarding Forward-Looking Information
This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, path to profitability, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “projecting”, “expect” or similar expressions and includes information regarding expectations for the Company's growth,
Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company’s shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
